Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. It is well tolerated and leads to no higher incidence of hemorrhagic events than other therapies. Of 87 patients we treated with IM for a minimum of 3 months, 10 patients (11%) developed unilateral or bilateral conjunctival hemorrhage (CH). No other hemorrhagic events were observed during follow-up, except for CH recurrence in 6 cases (7%). Because there was no other obvious reason for such a high incidence of CH, we hypothesize drug hypersensitivity or ocular irritation induced by IM treatment.
Conjunctival hemorrhagic events associated with imatinib / F. Radaelli, C. Vener, F. Ripamonti, A. Iurlo, M. Colombi, A. Artoni, G. Reda, G. Lambertenghi Deliliers. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 92:Suppl. 3(2007), pp. 180-180. (Intervento presentato al 41. convegno Congress of the Italian Society of Hematology tenutosi a Bologna nel 2007) [10.1532/IJH97.E0741].
Conjunctival hemorrhagic events associated with imatinib
C. VenerSecondo
;F. Ripamonti;G. RedaPenultimo
;G. Lambertenghi DeliliersUltimo
2007
Abstract
Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. It is well tolerated and leads to no higher incidence of hemorrhagic events than other therapies. Of 87 patients we treated with IM for a minimum of 3 months, 10 patients (11%) developed unilateral or bilateral conjunctival hemorrhage (CH). No other hemorrhagic events were observed during follow-up, except for CH recurrence in 6 cases (7%). Because there was no other obvious reason for such a high incidence of CH, we hypothesize drug hypersensitivity or ocular irritation induced by IM treatment.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
